The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer

Journal of Korean Medical Science

Volumn 24, Issue 2, 2009, Pages 275-280

  Min, Joo Won ^a   Um, Sang Won ^a   Yim, Jae Jun ^a   Yoo, Chul Gyu ^a   Han, Sung Koo ^a   Shim, Young Soo ^a   Kim, Young Whan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Alkaline Phosphatase; Bone Metastasis; Bone Scan; Fluorodeoxyglucose F18; Lung Neoplasms; PET CT

Indexed keywords

ALKALINE PHOSPHATASE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BLOOD; BONE TUMOR; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MEDICAL RECORD; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA; WHOLE BODY IMAGING;

AGED; ALKALINE PHOSPHATASE; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 67650345571     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.2.275     Document Type: Article

References (23)

1. Tritz DB, Doll DC, Ringenberg QS, Anderson S, Madsen R, Perry MC, Yarbro JW. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 1989; 63: 763-6.
2. Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 2004; 24: 3193-201.
3. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of nonsmall cell lung cancer: a review of the current evidence. Chest 2003; 123 (1 Suppl): 137S-46S.
4. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 1997; 76: 760-4.
5. Chung JH, Park MS, Kim YS, Chang J, Kim JH, Kim SK, Kim SK. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 2005; 46: 388-93.
6. Peterson JJ, Kransdorf MJ, O'Connor MI. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res 2003: S120-8.
7. Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004; 44: 317-25.
8. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25: 1244-7.
9. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with highrisk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT. J Nucl Med 2006; 47: 287-97.
10. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996; 199: 751-6.
11. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, Takahashi N, Honda H. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005; 19: 573-9.
12. Liu FY, Chang JT, Wang HM, Liao CT, Kang CJ, Ng SK, Chan SC, Yen TC. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 2006; 24: 599-604.
13. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002; 128: 325-8.
14. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Suzuki Y, Yasuda S, Shohtsu A. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-9.
15. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-9.
16. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002; 225: 575-81.
17. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, Altman H, Keidar Z, Israel O. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44: 1200-9.
18. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004; 45: 272-8.
19. Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, Dziuk K, Gabelmann A, Reske SN, Hetzel M. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42: 1800-4.
20. Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med 2001; 45: 47-52.
21. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998; 209: 253-8.
22. Alatas F, Alatas O, Metintas M, Colak O, Erginel S, Harmanci E. Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 2002; 35: 293-6.
23. Erturan S, Yaman M, Aydin G, Uzel I, Musellim B, Kaynak K. The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer. Chest 2005; 127: 449-54.